The inhibitors of tyrosine kinase;Os inibidores de tirosino quinase de segunda geração

Revista Brasileira de Hematologia e Hemoterapia

Volumn 30, Issue SUPPL. 1, 2008, Pages 37-40

  Delamain, Márcia Torresan ^a   Conchon, Mônika ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

AMN107; Chronic myeloid leukemia; Dasatinib; Imatinib resistant; Tyrosine kinase inhibitor

Indexed keywords

EID: 55949113877     PISSN: 15168484     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-84842008000500010     Document Type: Short Survey

References (14)

1. Jabbour E, Cortes J, Ghanem H, O'Brien, Kantarjian H. Target therapy in chronic myeloid leukemia. Expert Rev. Anticancer Ther. 2008;8(1):99-110.
2. Brave M, Goodman J, Kaminskas E. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistent to or intolerant of imatinib mesylate. Clin Câncer Res. 2008;14(2):352-9.
3. Keam S. Dasatinib. In chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Adis Drug Profile. 2008;22(1):59-69.
4. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005;11;4941-7.
5. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-41.
6. Manley P, Cowan-Jacob SW, Mestran J. Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukemia. Biochem Biophys Acta. 2005;1754:3-13.
7. Jabbour E, Corets J, O'Brien S, Giles F, Kantarjian H. New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin Hematol. 2007; 44(Suppl 1): S25-31.
8. Le Coutre P, Baskaynak G, Tamm I, et al. Activity and induction of apoptosis of the specific tyrosine kinase inhibitor AMN 107 in bcr-abl+ cell lines and in imatinib resistant primary cells from CML patients. Blood. 2004;104:218a.
9. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540-6.
10. G. Rosti, Le Coutre, K. Bhalla, F. Giles, G. Ossenkoppele, A. Hochhaus, et al. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No.18S (June 20 Suplement) 2007: 7007
11. Le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J. Gattermann, N, et al. Nilotinib (formerly AMN107), a highly selective BCRABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated phase chronic myelogenous leukemia. Prepublished on line Dec 2007; doi 10.1182-Blood-2007-04-830196.
12. Ottmann OG, Kantarijian H, Larson, et al. A phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib resistant or intolerant patients with chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph + acute lymphoblastic leukemia (ALL). Abstract. Paper presented at American Society of Hematology48th Annual Meeting; December9-12, 2006; Orlando, Fla.
13. Hochhaus A. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure. Expert Opinion. 2007;8(18):3257-64.
14. Hochhaus A. Management of Bcr-Abl-positive leukemias with dasatinib. Drug Profile. 2007;7(11):1529-36.